ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO727

Autoimmune and Genetic Workup in Post-Transplant C3 Glomerulopathy

Session Information

Category: Glomerular

  • 1004 Clinical/Diagnostic Renal Pathology and Lab Medicine


  • Kumar, Ashwani, Postgraduate Institute of Medical Education & Research, Chandigarh, India
  • Nada, Ritambhra, Postgraduate Institute of Medical Education & Research, Chandigarh, India
  • Ramachandran, Raja, Nehru Hospital, Chandigarh, India
  • Rayat, Charan Singh, Postgraduate Institute of Medical Education & Research, Chandigarh, India
  • Gupta, Krishan Lal L., Nehru Hospital, Chandigarh, India

Post-transplant C3 glomerulopathy (Tx-C3GP) is associated with alternate complement pathway (ACP) dysregulation and the literature is scanty. Hence, serological and genetic workup for Tx-C3GP was performed.


We performed Tx-C3GP workup in all patients reported during 2010-16. Tests included ACP functional assay (APFA), C3, C4 levels, complement factors H (CFH) and B (CFB) estimation. Paraproteins and autoantibodies to CFH (ab-CFH), CFB (ab-CFB), C3 convertase (C3Nef), PCR for CFH and complement factor H-related 5 (CFHR5) genes were done followed by Sanger sequencing. Clinical outcome of the patients was also recorded.


Twenty-six cases of Tx-C3GP included 11 cases of dense deposit disease (DDD), 10 C3 glomerulonephritis (C3GN) and 5 C3GP (EM not available). Mean age was 31.88 years. Two-thirds presented with graft dysfunction (Mean time; <1 week-C3GN, 8 Months-DDD). Nephrotic syndrome and asymptomatic urine abnormality were present in 17%. Basic disease was known in 50% (DDD-4, C3GN-3, C3GP-5, & Diabetic nephropathy-2) cases. Native kidney histology ranged from normal to membranoproliferative (MP) morphology, whereas in early post-transplant recurrences, it was focal segmental proliferative and MP in late recurrences. We observed low APFA and C3 in all cases. Positive findings in DDD included, low CFH levels, ab-CFH, low CFB levels in 56, 25 and 11%, respectively.

Low CFH levels (22%) and ab-CFH were present in 15% of C3GN. In contrast to DDD, 22% patients of C3GN had low CFB levels and ab-CFB (22%). C3NeF was positive in 44% DDD and 33% of C3GN. We found CFH SNP rs800292 (Val62Ile) in 44% and -18TT insertion in 22% cases of DDD and both SNPs were seen in 11% cases of tx-C3GN. SNP rs1061147 (p.Ala243Ala) and rs1061170 (p.His402Tyr) of CFH were more frequent in tx-C3GN (56% & 45%) and seen lesser in tx-DDD (33% and 11%). SNP rs2274700 (p.Ala473Ala) was equally present (22%) in both the groups. No variant of CFHR5 was present in any tx-C3GP case. 43% of the patients experienced graft loss.


Both DDD and C3GN reccur post-transplant. C3GN has an early recurrence compared to DDD. Low CFH and ab-CFH were evident in DDD, whereas low CFB and ab-CFB are seen in C3GN. Genetic findings for CFH gene revealed difference among variants for these two entities.


  • Government Support - Non-U.S.